Author:
Osorio J.C.,Ni A.,Chaft J.E.,Pollina R.,Kasler M.K.,Stephens D.,Rodriguez C.,Cambridge L.,Rizvi H.,Wolchok J.D.,Merghoub T.,Rudin C.M.,Fish S.,Hellmann M.D.
Funder
National Institutes of Health
National Cancer Institute
Fiona and Stanley Druckenmiller Center for Lung Cancer Research
KEYNOTE-001
Merck Sharp & Dohme, a subsidiary of Merck
Reference22 articles.
1. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma;Ribas;JAMA,2016
2. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015
3. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms;Parry;Mol Cell Biol,2005
4. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses;Bennett;J Immunol,2003
5. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death;Ishida;J. J,1992
Cited by
532 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献